naa a22 4500 510764312 CHVBK 20180411083151.0 cr unu---uuuuu 180411e20130501xx s 000 0 eng 10.1007/s12094-012-0942-8 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0942-8 Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC) [Elektronische Daten] [S. Keskin, I. Yıldız, F. Sen, F. Aydogan, L. Kilic, M. Ekenel, S. Saglam, B. Sakar, R. Disci, F. Aykan] Purpose: The aim of this retrospective study (from January 2007 to December 2011) was to investigate the efficacy and tolerability of mDCF schedule for chemotherapy-naïve AGC patients. Patients: Patients (n=54) with locally inoperable or distant metastasis and performance status of 0-2 were eligible. The triplet combination chemotherapy consisting of docetaxel 60mg/m2 on day 1, cisplatin 60mg/m2 on day 1, and 5-fluorouracil 600mg/m2 for 5days of continuous infusion were administered every 21days, up to nine cycles. Prophylactic G-CSF was not allowed. Results: In all, 36 (67%) patients were male and 18 (33%) were female; median age was 59years. The majority of patients (n=46, 85%) had metastatic disease and 8 (15%) of them had locally advanced disease. Liver metastasis and peritonitis carcinomatosa were found in 20 (43 %) and 18 (39%) of the 46 cases, respectively. The median cycle of chemotherapy was 6. In assessing 50 patients for response evaluation, one had complete response. Partial response was achieved in 27 (54%) patients. Seventeen patients (34%) had stable disease and 5 (10%) had progressive disease, while 4% (n=2) and 11% (n=6) of the patients developed severe (grade 3-4) neutropenia and anemia, respectively. During the median follow-up time (6.9months, range 0.4-24), 28 (52%) patients died. The overall and progression-free survival were 10.7 [95% CI 8.9-12.4] and 6.8 [95% CI 5.8-7.8] months, respectively. Conclusions: Although this was not a prospective comparative study, the mDCF regimen seems to be as effective as the original DCF in AGC with acceptable and manageable side effects. Federación de Sociedades Españolas de Oncología (FESEO), 2012 Modified DCF nationallicence Advanced gastric cancer nationallicence Efficacy nationallicence Adverse effect nationallicence Survival nationallicence Keskin S. Department of Medical Oncology, Institute of Oncology, University of Istanbul, Capa, 34093, Istanbul, Turkey aut Yıldız I. Department of Medical Oncology, Institute of Oncology, University of Istanbul, Capa, 34093, Istanbul, Turkey aut Sen F. Department of Medical Oncology, Institute of Oncology, University of Istanbul, Capa, 34093, Istanbul, Turkey aut Aydogan F. Department of Medical Oncology, Institute of Oncology, University of Istanbul, Capa, 34093, Istanbul, Turkey aut Kilic L. Department of Medical Oncology, Institute of Oncology, University of Istanbul, Capa, 34093, Istanbul, Turkey aut Ekenel M. Department of Medical Oncology, Institute of Oncology, University of Istanbul, Capa, 34093, Istanbul, Turkey aut Saglam S. Department of Medical Oncology, Istanbul Bilim University, Istanbul, Turkey aut Sakar B. Department of Medical Oncology, Institute of Oncology, University of Istanbul, Capa, 34093, Istanbul, Turkey aut Disci R. Department of Public Health, Faculty of Medicine, University of Istanbul, Istanbul, Turkey aut Aykan F. Department of Medical Oncology, Institute of Oncology, University of Istanbul, Capa, 34093, Istanbul, Turkey aut Clinical and Translational Oncology Springer Milan 15/5(2013-05-01), 403-408 1699-048X 15:5<403 2013 15 12094 https://doi.org/10.1007/s12094-012-0942-8 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0942-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Keskin S. Department of Medical Oncology, Institute of Oncology, University of Istanbul, Capa, 34093, Istanbul, Turkey aut NATIONALLICENCE 700 1- Yıldız I. Department of Medical Oncology, Institute of Oncology, University of Istanbul, Capa, 34093, Istanbul, Turkey aut NATIONALLICENCE 700 1- Sen F. Department of Medical Oncology, Institute of Oncology, University of Istanbul, Capa, 34093, Istanbul, Turkey aut NATIONALLICENCE 700 1- Aydogan F. Department of Medical Oncology, Institute of Oncology, University of Istanbul, Capa, 34093, Istanbul, Turkey aut NATIONALLICENCE 700 1- Kilic L. Department of Medical Oncology, Institute of Oncology, University of Istanbul, Capa, 34093, Istanbul, Turkey aut NATIONALLICENCE 700 1- Ekenel M. Department of Medical Oncology, Institute of Oncology, University of Istanbul, Capa, 34093, Istanbul, Turkey aut NATIONALLICENCE 700 1- Saglam S. Department of Medical Oncology, Istanbul Bilim University, Istanbul, Turkey aut NATIONALLICENCE 700 1- Sakar B. Department of Medical Oncology, Institute of Oncology, University of Istanbul, Capa, 34093, Istanbul, Turkey aut NATIONALLICENCE 700 1- Disci R. Department of Public Health, Faculty of Medicine, University of Istanbul, Istanbul, Turkey aut NATIONALLICENCE 700 1- Aykan F. Department of Medical Oncology, Institute of Oncology, University of Istanbul, Capa, 34093, Istanbul, Turkey aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/5(2013-05-01), 403-408 1699-048X 15:5<403 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer